Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Janssen is paying the South Korean drugmaker Yuhan $50 million to develop its drug candidate lazertinib, which is being tested in people with non-small-cell lung cancers, including ones with brain metastases. Yuhan could receive up to $1.2 billion in future payments from Janssen. Lazertinib is an epithelial growth factor tyrosine-kinase inhibitor. Another drug of that class, AstraZeneca’s Tagrisso, was approved in the U.S. in April and is expected to bring in billions of dollars.
CORRECTION: On Nov. 14, 2018, this story was updated to correct the structure of lazertinib. The original structure was missing a nitrogen.
This article has been sent to the following recipient: